A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

por Goldstein, Daniel A., Clark, Jonathon, Tu, Yifan, Zhang, Jie, Fang, Fenqi, Goldstein, Robert, Stemmer, Salomon M., Rosenbaum, Eli
Publicado 2017

The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States

por Moore, Assaf, Stav, Ido, Den, Robert B., Gordon, Noa, Sarfaty, Michal, Neiman, Victoria, Rosenbaum, Eli, Goldstein, Daniel A.
Publicado 2019

Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients

por Brait, Mariana, Banerjee, Mithu, Maldonado, Leonel, Ooki, Akira, Loyo, Myriam, Guida, Elisa, Izumchenko, Evgeny, Mangold, Leslie, Humphreys, Elizabeth, Rosenbaum, Eli, Partin, Alan, Sidransky, David, Hoque, Mohammad Obaidul
Publicado 2017

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

por Keizman, Daniel, Frenkel, Moshe, Peer, Avivit, Rosenbaum, Eli, Sarid, David, Leibovitch, Ilan, Mano, Roy, Yossepowitch, Ofer, Wolf, Ido, Geva, Ravit, Margel, David, Rouvinov, Keren, Stern, Anat, Dresler, Hadas, Kushnir, Igal, Eliaz, Isaac
Publicado 2023

Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study

por Margel, David, Benjaminov, Ofer, Ozalvo, Rachel, Shavit Grievink, Liat, Kedar, Inbal, Yerushalmi, Rinat, Ben-Aharon, Irit, Neiman, Victoria, Yossepowitch, Ofer, Kedar, Daniel, Levy, Zohar, Shohat, Mordechai, Brenner, Baruch, Baniel, Jack, Rosenbaum, Eli
Publicado 2014

Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse

por Rijensky, Nataly Mancette, Blondheim Shraga, Netta R., Barnea, Eilon, Peled, Nir, Rosenbaum, Eli, Popovtzer, Aron, Stemmer, Solomon M., Livoff, Alejandro, Shlapobersky, Mark, Moskovits, Neta, Perry, Dafna, Rubin, Eitan, Haviv, Itzhak, Admon, Arie
Publicado 2020

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

por Keizman, Daniel, Frenkel, Moshe, Peer, Avivit, Kushnir, Igal, Rosenbaum, Eli, Sarid, David, Leibovitch, Ilan, Mano, Roy, Yossepowitch, Ofer, Margel, David, Wolf, Ido, Geva, Ravit, Dresler, Hadas, Rouvinov, Keren, Rapoport, Noa, Eliaz, Isaac
Publicado 2021

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors

por Goldstein, Daniel A., Ginsberg, Gary M., Hofnung-Gabbay, Dorit, De Abreu Lourenco, Richard, Loong, Herbert H., Goh, Boon Cher, Chan, Kelvin K. W., Di Maio, Massimo, Perrone, Francesco, Hall, Peter S., Zer, Alona, Rosenbaum, Eli
Publicado 2023

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases...

por Sartor, Oliver, Heinrich, Daniel, Mariados, Neil, Méndez Vidal, Maria José, Keizman, Daniel, Thellenberg Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Rosenbaum, Eli, Severi, Stefano, Trigo, José, Trandafir, Lucia, Wagner, Volker, Li, Rui, Nordquist, Luke T.
Publicado 2019

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

por Rouvinov, Keren, Levanon, Eran, Peer, Avivit, Sarfaty, Michal, Sarid, David, Neiman, Victoria, Grikshtas, Eduard, Rosenbaum, Eli, Kushnir, Igal, Talmor, Barak, Friger, Michael, Zarbiv, Yonaton, Gez, Eli, Dresler, Hadas, Shalata, Walid, Meirovitz, Amichay, Shrem, Noa Shani, Yakobson, Alexander, Mermershtain, Wilmosh, Keizman, Daniel
Publicado 2023

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

por Sternberg, Cora N., Petrylak, Daniel P., Bellmunt, Joaquim, Nishiyama, Hiroyuki, Necchi, Andrea, Gurney, Howard, Lee, Jae-Lyun, van der Heijden, Michiel S., Rosenbaum, Eli, Penel, Nicolas, Pang, See-Tong, Li, Jian-Ri, García del Muro, Xavier, Joly, Florence, Pápai, Zsuzsanna, Bao, Weichao, Ellinghaus, Peter, Lu, Chengxing, Sierecki, Mitchell, Coppieters, Sabine, Nakajima, Keiko, Ishida, Tatiane Cristine, Quinn, David I.
Publicado 2023

A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy

por Golan, Shay, Bar, Vered, Salpeter, Seth J., Neev, Guy, Creiderman, German, Kedar, Daniel, Aharon, Sara, Turovsky, Lubov, Zundelevich, Adi, Shahar, Hamutal, Shapira, Hagit, Mallel, Giuseppe, Stossel, Erez, Gavert, Nancy, Straussman, Ravid, Dotan, Zohar, Berger, Raanan, Stossel, Chani, Golan, Talia, Halperin, Sharon, Leibovici, Dan, Breuer, Shani, Rottenberg, Yakir, Applebaum, Liat, Hubert, Ayala, Nechushtan, Hovav, Peretz, Tamar, Zick, Aviad, Chertin, Boris, Koulikov, Dmitry, Sonnenblick, Amir, Rosenbaum, Eli
Publicado 2023

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEY...

por Antonarakis, Emmanuel S., Park, Se Hoon, Goh, Jeffrey C., Shin, Sang Joon, Lee, Jae Lyun, Mehra, Niven, McDermott, Ray, Sala-Gonzalez, Núria, Fong, Peter C., Greil, Richard, Retz, Margitta, Sade, Juan Pablo, Yanez, Patricio, Huang, Yi-Hsiu, Begbie, Stephen D., Gafanov, Rustem Airatovich, De Santis, Maria, Rosenbaum, Eli, Kolinsky, Michael P., Rey, Felipe, Chiu, Kun-Yuan, Roubaud, Guilhem, Kramer, Gero, Sumitomo, Makoto, Massari, Francesco, Suzuki, Hiroyoshi, Qiu, Ping, Zhang, Jinchun, Kim, Jeri, Poehlein, Christian H., Yu, Evan Y.
Publicado 2023